secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001628280-24-022466
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine Q1 net loss $45.8M; FDA clears IND for CGD Prime Editing therapy
-------------------------------------------------------------------------------

- Net loss $45.8M (vs $39.4M Q1 2023); cash $224.2M as of March 31, 2024.
- FDA cleared IND for PM359 for chronic granulomatous disease—first Prime Editing product to enter clinic.
- Phase 1/2 trial planned; initial clinical data expected in 2025.
- Appointed Tony Coles, M.D. as senior advisor; brings biopharma leadership.
- Presented preclinical data at ASGCT supporting specificity and delivery of Prime Editing platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024022466/0001628280-24-022466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024022466/prme-20240510.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-022466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer